INS and cancer: In the current study, the PharmMapper server with pharmacophore reverse screening technology was employed to investigate and predict the potential anti-diabetic targets of carainterol A. The pathway enrichment was analyzed using ClueGO software and the results suggested that carainterol A might have an influence on the insulin signaling pathway and the cancer-related pathway.